About: Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 1998

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 1998 (uk) article scientifique publié en 1998 (fr) im Juni 1998 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunu de 1998 (ast) scientific article published on 01 June 1998 (en)
publication date	wds:Q74820371-8F41B1C3-CFA4-40CD-89E1-92F6D4592ECD
publication date	1998-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q74820371-BBB39223-423D-44D0-B39E-0200DB282550
language of work or name	English
cites work	wds:Q74820371-151341D1-CBFE-4A51-9327-44FAD0E26B64 wds:Q74820371-1ECFF00D-D039-4381-9143-7A2B7360C270 wds:Q74820371-35BDA36F-6A40-4459-931C-7A024879682B wds:Q74820371-39E2F430-586F-4D48-946B-D54CFA97ADFA wds:Q74820371-46F00DD8-7382-4474-B062-342EB6BD20CC wds:Q74820371-472E5D68-D952-48A4-9E48-A8B3C2DFB535 wds:Q74820371-5D476726-EADF-48D3-B406-3FF2084B88E6 wds:Q74820371-647AAC9C-49A0-48A5-9C80-49EFDCEC8BFD wds:Q74820371-663A11A7-F4E6-49BE-BC86-22DEEB0CC899 wds:Q74820371-8B837181-AF99-4BD0-9596-B3A782A6E689 wds:Q74820371-8D371182-0309-4B0E-8BF6-79AEABEAA76A wds:Q74820371-8DA3A966-D4B5-4A21-84E2-444F27A828B7 wds:Q74820371-92CA6DC6-EF5B-45CC-BC67-F3C9D22CF8A0 wds:Q74820371-95795529-B977-4E73-A1DF-25913448594B wds:Q74820371-9D354D54-78D0-4C00-AB12-BE16AF400944 wds:Q74820371-A3FD8E4B-4992-45CC-8A2A-5D23C229BBB4 wds:Q74820371-AA363906-A12B-4FE3-B8B6-EE61903F72B5 wds:Q74820371-C1C4D850-4D12-4DA5-816E-6880C7AF27EE wds:Q74820371-C83E67BF-BDFB-4818-85E4-0E2566F98DE3 wds:Q74820371-C9EEDC8E-0679-4987-AA59-20ECDA2C641B wds:Q74820371-F4A1E4A7-12F6-46DA-9414-A1C01DBA4418
cites work	American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer Nonparametric Estimation from Incomplete Observations Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer Effects of CPT-11 in combination with other anti-cancer agents in culture Toxicity and response criteria of the Eastern Cooperative Oncology Group Confidence intervals for reporting results of clinical trials European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. Treatment of recurrent gynaecologic malignancies with a new camptothecin derivative
author name string	wds:Q74820371-6B5A9866-BC32-459D-B413-27E661494CBF wds:Q74820371-71E97A0B-5193-4BE8-9639-298455CEA7CA wds:Q74820371-7224578E-AFCC-4A8D-9E7B-13CDE6B040FF wds:Q74820371-937FD530-5B2F-493B-9647-FCE0290057D0 wds:Q74820371-9794445E-F328-41AD-B24C-11C17E0F1F99 wds:Q74820371-BBEFE88E-F0F4-4BB0-8000-2914530B53A6 wds:Q74820371-D0A1AF7D-6AC0-41E2-A2F2-B478B83EDB03
author name string	T Nishida T Sugiyama M Yakushiji K Ushijima J Kigawa N Terakawa N Okura
rdfs:label	Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer (en) Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer (nl)
skos:prefLabel	Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer (en) Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer (nl)
name	Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer (en) Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer (nl)
title	wds:Q74820371-DDAE3AC4-25B5-423D-A30C-6E50C37D8BF2
title	Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer (en)
page(s)	wds:Q74820371-5E6734A0-0905-4EF0-91BD-862785273284
page(s)	211-218
instance of	wds:Q74820371-2E974B24-DB38-4EA4-956B-DFC354DB833D
instance of	scholarly article
main subject	wds:Q74820371-86BA22C5-1202-4C6E-BC90-1F7F47DBDA88 wds:Q74820371-B50E246D-EABB-4AA3-8725-1C7E2BD0848A wds:Q74820371-CAA0D0FA-F45D-4D15-9F87-7DAE9731B77D
main subject	irinotecan ovarian neoplasm cisplatin
PubMed ID	wds:Q74820371-CA6E2635-7BBC-4F45-A07D-BE7081CCFEBC
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9683285
PubMed ID	9683285
published in	wds:Q74820371-8ABDC4E9-94E2-4C92-86AD-ED84A685B146
published in	Cancer Letters
issue	wds:Q74820371-5F987B1B-31FD-464D-8B51-278AC0D250D5
volume	wds:Q74820371-EC74C583-2C38-4CE5-9731-1A202FB723B2
issue	2
volume	128
DOI	wds:Q74820371-28F01BB2-A42D-4228-B370-EC1D3C760108
DOI	http://dx.doi.org/10.1016/S0304-3835(98)00065-2
DOI	10.1016/S0304-3835(98)00065-2
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q74820371
is cites work of	Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software